

Corline Biomedical Q4 - Focus on Kardium's market launch

Redeye provides an update following Corline's Q4 2024 report. The report itself was relatively undramatic; however, we look forward to an eventful 2025. We make some model changes, but our fair value range remains intact.

[Read more and download the Research Update.](#)

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

[Corline Biomedical Q4 - Focus on Kardium's market launch](#)